Finzati - Logo
SLXN logo

Silexion Therapeutics Ltd.

SLXN • Biotechnology
$0.35
▲ +0.00 (+0.06%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$176,062
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.18Healthy liquidity · 2.41Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:26 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.35
Change0.06%
Market Cap$176.06K
Beta-0.25
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.18
Current Ratio2.41
Quick Ratio2.41
Volume985.97K
Avg Volume562.54K

Investment DNA

How strong this company looks for long-term investors

50
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0.18Healthy liquidity · 2.41Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 8/16/2024
Industry: Biotechnology
P/B i: 0.98
Debt / Equity i: 0.18
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.18
Current Ratio: 2.41
Quick Ratio: 2.41
Status: Strong

Insider Transactions

Recent executive and insider activity

Hadar Ilan
Transaction: 06/04/2026
BUY
Change
+10,000
Price
Not reported
Filing
06/08/2026
Type
BUY
Horenshtein Hadar Mirit
Transaction: 06/04/2026
BUY
Change
+7,500
Price
Not reported
Filing
06/08/2026
Type
BUY
Shirvan Mitchell
Transaction: 06/04/2026
BUY
Change
+6,000
Price
Not reported
Filing
06/08/2026
Type
BUY